drugset
drugset / Trial / NCT04060719

A Study in Healthy Men to Test Whether Rifampicin Influences the Amount of BI 894416 in the Blood

NCT04060719 ↗

Phase 1 Completed 16 enrolled Boehringer Ingelheim
Non-randomizedCrossoverOpen-labelTreatment

Summary

The main objective of this trial is to investigate the effect of rifampicin on the pharmacokinetics of BI 894416.

Timeline

Start
2019-09-04
Primary completion
2019-10-17
Completion
2019-10-17

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 894416 Unknown — Oral
Subject Rifampicin Small molecule — —

Indications

No indication recorded.